Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. Issue 1 (5th January 2022) - Tapete, Gherardo; Bertani, Lorenzo; Pieraccini, Alberto; Lynch, Erica Nicola; Giannotta, Martina; Morganti, Riccardo; Biviano, Ivano; Naldini, Sara; Mumolo, Maria Gloria; De Nigris, Francesca; Calella, Francesca; Bagnoli, Siro; et al.